Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment

Table 1

Serum concentrations of measured parameters in healthy controls and patients with multiple myeloma.

	𝑛	Mean ± SD	𝑃 (Mann Whitney)
OPG pmol/L
Control	20	6.4±5.3	< 0.03
Patients	54	12.5±11.5
RANKL pmol/L
Control	20	13.54±9.90	= 0.007
Patients	54	364.48±393.63
RANKL/OPG
Control	20	14.44±28.39	NS
Patients	54	51.69±70.77
HGF pg/mL
Control	20	465.3±163.4	< 0.001
Patients	54	1612.2±1107.5
LDH IU/L
Control	20	163.1±36.4	< 0.01
Patients	54	228.9±77.2
VEGF pg/mL
Control	20	90.2±14.4	< 0.001
Patients	54	272.3±178.7
B2M mg/dL
Control	20	1.5±0.6	< 0.001
Patients	54	3.9±3.8
CRP mg/L
Control	20	0.4±0.1	< 0.001
Patients	54	1.1±1.3
IL-6 pg/mL
Control	20	0.8±0.5	< 0.001
Patients	54	6.4±5.1